D. Ross Camidge, M.D., Ph.D., University of Colorado Cancer Center (IMAGE)

University of Colorado Anschutz

D. Ross Camidge, M.D., Ph.D., University of Colorado Cancer Center

Caption

D. Ross Camidge, M.D., Ph.D., and colleagues show 51 percent reduction in risk of death over course of phase III ALTA-1 trial with brigatinib compared with cirzotinib.

Credit

University of Colorado Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.